X4 Pharmaceuticals (XFOR) Invested Capital (2018 - 2025)
Historic Invested Capital for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $136.6 million.
- X4 Pharmaceuticals' Invested Capital rose 148.42% to $136.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.6 million, marking a year-over-year increase of 148.42%. This contributed to the annual value of $97.1 million for FY2024, which is 843.55% down from last year.
- Latest data reveals that X4 Pharmaceuticals reported Invested Capital of $136.6 million as of Q3 2025, which was up 148.42% from $79.0 million recorded in Q2 2025.
- X4 Pharmaceuticals' 5-year Invested Capital high stood at $169.5 million for Q2 2024, and its period low was $56.0 million during Q1 2024.
- In the last 5 years, X4 Pharmaceuticals' Invested Capital had a median value of $100.0 million in 2023 and averaged $104.5 million.
- Within the past 5 years, the most significant YoY rise in X4 Pharmaceuticals' Invested Capital was 7478.76% (2025), while the steepest drop was 5339.6% (2025).
- Over the past 5 years, X4 Pharmaceuticals' Invested Capital (Quarter) stood at $96.9 million in 2021, then rose by 9.95% to $106.6 million in 2022, then fell by 0.42% to $106.1 million in 2023, then dropped by 8.44% to $97.1 million in 2024, then soared by 40.63% to $136.6 million in 2025.
- Its Invested Capital stands at $136.6 million for Q3 2025, versus $79.0 million for Q2 2025 and $97.9 million for Q1 2025.